Equitable Trust Co. Sells 1,445 Shares of HCA Healthcare, Inc. $HCA

Equitable Trust Co. trimmed its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 0.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 158,439 shares of the company’s stock after selling 1,445 shares during the quarter. HCA Healthcare comprises 3.3% of Equitable Trust Co.’s portfolio, making the stock its 4th biggest holding. Equitable Trust Co.’s holdings in HCA Healthcare were worth $73,969,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in HCA. Palisade Asset Management LLC acquired a new stake in shares of HCA Healthcare in the third quarter valued at about $26,000. Holos Integrated Wealth LLC acquired a new stake in shares of HCA Healthcare in the fourth quarter valued at about $29,000. Ares Financial Consulting LLC acquired a new stake in shares of HCA Healthcare in the fourth quarter valued at about $31,000. JPL Wealth Management LLC acquired a new stake in HCA Healthcare during the third quarter worth about $33,000. Finally, Aventura Private Wealth LLC acquired a new stake in HCA Healthcare during the fourth quarter worth about $34,000. 62.73% of the stock is owned by institutional investors and hedge funds.

HCA Healthcare Stock Performance

HCA Healthcare stock opened at $428.94 on Wednesday. The firm has a market cap of $95.16 billion, a P/E ratio of 14.75, a P/E/G ratio of 1.36 and a beta of 1.18. The business’s fifty day moving average is $495.58 and its two-hundred day moving average is $486.47. HCA Healthcare, Inc. has a 52 week low of $330.00 and a 52 week high of $556.52.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Friday, April 24th. The company reported $7.15 EPS for the quarter, missing analysts’ consensus estimates of $7.19 by ($0.04). The business had revenue of $19.11 billion during the quarter, compared to analyst estimates of $19.09 billion. HCA Healthcare had a negative return on equity of 295.93% and a net margin of 8.89%.HCA Healthcare’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.45 EPS. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. On average, equities research analysts predict that HCA Healthcare, Inc. will post 30.05 earnings per share for the current year.

HCA Healthcare Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 16th will be given a $0.78 dividend. This represents a $3.12 annualized dividend and a yield of 0.7%. The ex-dividend date is Tuesday, June 16th. HCA Healthcare’s payout ratio is 10.73%.

Insider Buying and Selling

In related news, EVP Michael R. Mcalevey sold 1,694 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $533.37, for a total value of $903,528.78. Following the completion of the transaction, the executive vice president owned 8,853 shares in the company, valued at $4,721,924.61. The trade was a 16.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Christopher F. Wyatt sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $505.00, for a total transaction of $2,020,000.00. Following the completion of the transaction, the senior vice president owned 44,379 shares of the company’s stock, valued at $22,411,395. This trade represents a 8.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 13,714 shares of company stock worth $7,050,460 in the last quarter. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

HCA has been the topic of a number of recent research reports. Oppenheimer decreased their target price on HCA Healthcare from $540.00 to $520.00 and set an “outperform” rating on the stock in a research report on Monday, April 27th. Jefferies Financial Group reissued a “buy” rating and set a $525.00 target price on shares of HCA Healthcare in a research report on Friday, April 24th. Leerink Partners decreased their target price on HCA Healthcare from $573.00 to $500.00 and set an “outperform” rating on the stock in a research report on Monday, April 27th. JPMorgan Chase & Co. raised their price target on shares of HCA Healthcare from $420.00 to $535.00 and gave the stock a “neutral” rating in a research note on Friday, February 20th. Finally, Sanford C. Bernstein cut their price target on shares of HCA Healthcare from $541.00 to $503.00 and set a “market perform” rating for the company in a research note on Tuesday, April 28th. Sixteen analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, HCA Healthcare has an average rating of “Moderate Buy” and an average target price of $517.82.

HCA Healthcare Profile

HCA Healthcare is a for?profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.